Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 22, 13:30-17:30
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
Stay tuned
13:30-13:50 Cross-Border BD Transactions: Lessons Learned and Best Practices
Gerry Zhao: Partner, JunHe LLP
13:50-14:05 From License-out to Evidence-Ready: The Next Phase of Global Business Development for Chinese Innovative Biopharma
Erdong Cheng: Managing Director, Custom Solutions, APAC Norstella
14:05-14:20 Statistics-Driven Global Business Development
Zhenming Xun: Former Global Head of Biostatistics and Data Management, Daiichi Sankyo
14:20-14:35 Tax Considerations for Cross-Border BD Transactions and Overseas Investment in Innovative Biopharma
TBD, Ernst & Young
14:35-14:50 Intellectual Property Considerations for Collaborations with U.S. Pharmaceutical Companies
Yieyie Yang: Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
14:50-15:05 Deepen Cross-border Financial Services to Fully Support Enterprises in Overseas Business Development
Alice Song: Head of International Business Department, Bank of Jiangsu Shanghai Branch
15:05-16:00 Nuts, Bolts and Best Practices of Cross-Border BD and Investment Deals
Jimmy Zhang (Moderator): Executive Mentor, QB3/Bakar Labs, UC Berkeley
Albert Ren: Vice President, Head of WWBD China, Pfizer
John Zhu: Founder, Chairman and CEO of Duality Bio
Chen Ming Yu: Founder & Managing Partner, TCG Crossover
Kevin Guan: Lawyer of Goodwin’s Asia Life Sciences
Jenkins Fung: Head of North Asia ex-Japan at SS&C Intralinks
16:00-16:40 Panel Discussion I: Advancing Global Collaboration for Innovative Medicines: Strategy, Capabilities, and Value Creation
Han Dai (Planner & Moderator): Chief Innovation Officer, Head of Investment & Strategy, Vivarium
Dan Wang: Head of External Scientific Innovation Asia Pacific, Johnson & Johnson
Fred Li: Director, Search & Evaluation, Novartis China
Frank Luo: Associate Vice President, Simcere Zaiming (North America and Europe BD)
Yi Ding: BD Director, RA Swiftbridge
Morgan Xu: Partner, Foley Hoag LLP
16:40-17:30 Panel Discussion II: Reimagining the Biopharma BD Ecosystem: Multi-Stakeholder Collaboration and Emerging Paradigms
Mingde Xia (Moderator): Founder, Chairman & CEO, Innolake Biopharm
Jenny Yang: Head of External Innovation, Asia Pacific, Novo Nordisk A/S
Jian Lin: Senior Director, External Innovation, JNJ
Dong Chen: Executive Director, External Innovation, AbbVie
Betty Huang: VP and Head of Collaborate to Cure Hub China, Bayer Pharmaceuticals
Hao Huang: Head of the New Business for Marketing Solutions, LinkedIn China
Shuai Chen: Deputy General Manager, Overseas Business Department, Bank of Ningbo (NBCB)